PRELIMINARY SCIENTIFIC PROGRAM

Thursday, June 13, 2024

8:00 - 8:30 AM    Welcome Coffee

8:30 AM - 8:40 AM    Introduction on behalf of the scientific committee by Alexandre Mebazaa (Paris, FRA)

8:40 AM - 10:30 AM

Session 1: Cardiogenic Shock: Time for paradigm shift!

Moderated by Christopher O'Connor (Falls Church, USA) and Hannah Schaubroeck (Brussels, BEL)

Speakers (10 minutes each)

• CS trials: a new approach is needed: Susanna Price (London, GBR)

• Lessons from ECLS-Shock: Holger Thiele (Leipzig, GER)

• Further lessons from DAN-GER: Jacob Møller (Odense, DEN)

• Lessons from observational studies: Pascal Leprince (Paris, FRA)

• Dealing with heteregoneity in care: Erin Bohula (Boston, USA)

• Global networking is key: Navin Kapur (Boston, USA)

• Toward personalized management!: Vanessa Blumer (Falls Church, USA)

Panel discussion

Moderated by Christopher O'Connor (Falls Church, USA) and Hannah Schaubroeck (Brussels, BEL)

Susanna Price (London, GBR), Holger Thiele (Leipzig, GER), Jacob Møller (Odense, DEN), Pascal Leprince (Paris, FRA), Erin Bohula (Boston, USA), Navin Kapur (Boston, USA), Vanessa Blumer (Falls Church, USA), Keith Aaronson (FDA, USA), EMA, NIH/NHLBI

Paper: Vanessa Blumer (Falls Church, USA) & Connor O’Brien (San Francisco, USA)

10:30 - 10:50 AM   Coffee Break

10:50 AM - 12:00 PM

Session 2: Cardiogenic Shock: Inflammation: a driver of outcome

Moderated by Janine Pöss (Leipzig, GER) & Jason Katz (New York, USA)

Speakers (10 minutes each)

• Inflammation markers and Cardiogenic Shock phenotypes: Sabri Soussi (Toronto, CAN)

• Genotyping: Alastair Proudfoot (London, GBR)

• Phase 2 cardiac surgery trial design: Peter Pickkers (Nijmegen, NED)

• New biomarkers (IL6 and DPP3): Florian Wenzl (Zürich, SUI)

• Inhibition of DPP3 & inflammation: Ferie Azibani (Paris, FRA)

• DOBERMANN trial: Helle Søholm (Copenhagen, DEN)

Panel discussion

Moderated by Janine Pöss (Leipzig, GER) & Jason Katz (New York, USA)

Sabri Soussi (Toronto, CAN), Alastair Proudfoot (London, GBR), Peter Pickkers (Nijmegen, NED), Florian Wenzl (Zürich, SUI), Ferie Azibani (Paris, FRA), Helle Søholm (Copenhagen, DEN), EMA, NIH/NHLBI

Paper: Helle Søholm (Copenhagen, DEN) & Florian Wenzl (Zürich, SUI)

12:00 - 1:00 PM Lunch Break

1:00 PM - 3:20 PM

Session 3: Improve Cardiogenic Shock trial design to prevent neutral trial

Moderated by William O'Neill (Detroit, USA) and Susanna Price (London, GBR)

Speakers (10 minutes each)

• We need positive trials: Rhonda Monroe (Charlotte, USA)

• Randomization by patient is not appropriate: Alexandre Mebazaa (Paris, FRA)

• Is clustering by center the answer?: Brian Cuthbertson (Toronto, CAN)

• Control arm should remain "control": Rebecca Mathew (Ottawa, CAN)

• Post-device period is very important: Roberta Bogaev Chapman (Abiomed, USA)

• SOC in a device trial: a challenge: Navin Kapur (Boston, USA)

• Should we include cardiac arrest?: Uwe Zeymer (Ludwigshafen, GER)

• Registry-based randomised trials: David Morrow (Boston, USA)

• eCPR: Roberto Lorusso (Maastricht, NED)

• Win Ratio in critical care: are we ready?: Harriette Van Spall (Hamilton, CAN)

• Industry perspective: Nitin Salunke (Supira Medical, USA)

Panel discussion

Moderated by William O'Neill (Detroit, USA) and Susanna Price (London, GBR)

Rhonda Monroe (Charlotte, USA), Alexandre Mebazaa (Paris, FRA), Brian Cuthbertson (Toronto, CAN), Rebecca Mathew (Ottawa, CAN), Roberta Bogaev Chapman (Abiomed, USA), Navin Kapur (Boston, USA), Uwe Zeymer (Ludwigshafen, GER), David Morrow (Boston, USA), Jan Belohlavek (Prague, CZE), Roberto Lorusso (Maastricht, NED), Harriette Van Spall (Hamilton, CAN), Nitin Salunke (Supira Medical, USA), Chang Fu Wu (FDA,USA), Bram Zuckerman (FDA, USA), EMA, NIH/NHLBI

Paper: Antoine Kimmoun (Nancy, FRA) & TBD

3:20 - 3:40 PM Coffee Break

3:40 PM - 4:50 PM

Session 4: Ongoing studies

Moderated by Alessandro Sionis (Barcelona, ESP) and Anu Lala (New York, USA)

Discussants (5 minutes each)

• DOREMI2: Rebecca Mathew (Ottawa, CAN)

• RECOVER IV: William O'Neill (Detroit, USA)

• Unload VA-ECMO + Impella: Dirk Westermann (Freiburg, GER)

• Altshock-2: Alice Sacco (Milan, ITA)

• ANCHOR: Alain Combes (Paris, FRA)

• LevoHeartShock: Bruno Levy (Nancy, FRA)

• CERAMICS: Mir Babar Basir (Detroit, USA)

• PACCS: Manreet Kanwar (Pittsburgh, USA)

• IV-cangrelor STEMI shock: Sarah Gorgis (Cleveland, USA)

• Continuous Cerebral Autoregulation Monitoring in ECMO Patients - a pilot study: Lucy Zhang (Falls Church, USA)

• Pharmacologic Optimization of Mechanical Support in Cardiogenic Shock – A New Paradigm: Balimkiz Senman (Durham, USA)

• Industry perspective: Allen Waziri (iCE Neurosystems, USA)

Panel discussion

Moderated by Alessandro Sionis (Barcelona, ESP) and Anu Lala (New York, USA)

Rebecca Mathew (Ottawa, CAN), William O'Neill (Detroit, USA), Dirk Westermann (Freiburg, GER), Alice Sacco (Milan, ITA), Alain Combes (Paris, FRA), Bruno Levy (Nancy, FRA), Mir Babar Basir (Detroit, USA), Manreet Kanwar (Pittsburgh, USA), Sarah Gorgis (Cleveland, USA), Lucy Zhang (Falls Church, USA), Allen Waziri (iCE Neurosystems, USA), EMA, NIH/NHLBI

Paper: Mireia Padilla Lopez (Barcelona, ESP)

4:50 - 5:00 PM Coffee Break

5:00 PM - 6:45 PM

Session 5: Positive trials in critical care: the key role of regulators

Moderated by Mona Fiuzat (Arlington, USA), Alexandre Mebazaa (Paris, FRA) and Rhonda Monroe (Charlotte, USA)

Discussants (5 minutes each)

• Patient's Perspective: Rhonda Monroe (Charlotte, USA)

• Investigator Perspective: EU: Thomas Lüscher (Zurich, SUI)

• Investigator Perspective: US: Mitchell Krucoff (Durham, USA)

• Investigator Perspective: Japan: Naoki Sato (Tokyo, JPN)

• Scientific Press perspective: Stuart Spencer (The Lancet, USA)

• Industry Perspective: Chuck Simonton (Abiomed, USA), Andres Beiras (Getinge, GER), Karine Bourgeois (4TEEN4, GER), Liesbeth Hof (AM-Pharma, NED)

• Regulators' Perspective: FDA: Ileana Piña (Cleveland, USA), Andrew Farb (FDA, USA) & Norman Stockbridge (FDA, USA)

• Regulators' Perspective: Maciej Kostrubiec (EMA, POL)

• Regulators' Perspective: Shuichi Mochizuki (PMDA, JPN)

• NIH Perspective: George Sopko (NHLBI, USA)

Panel discussion

Moderated by Mona Fiuzat (Arlington, USA), Alexandre Mebazaa (Paris, FRA) and Rhonda Monroe (Charlotte, USA)

David Baran (Fort Lauderdale, USA), Rhonda Monroe (Charlotte, USA), Thomas Lüscher (Zurich, SUI), Mitchell Krucoff (Durham, USA), Naoki Sato (Tokyo, JPN), Stuart Spencer (The Lancet, USA), Chuck Simonton (Abiomed, USA), Andres Beiras (Getinge, GER), Karine Bourgeois (4TEEN4, GER), Liesbeth Hof (AM-Pharma, NED), Ileana Piña (Cleveland, USA), Andrew Farb (FDA, USA), Norman Stockbridge (FDA, USA), Maciej Kostrubiec (EMA, POL), Shuichi Mochizuki (PMDA, JPN), George Sopko (NHLBI, USA), Kathleen Grunder (FDA, USA) & Mauro Moscucci (FDA, USA)

Paper: TBD

6:45 PM - 7:00 PM

Take home messages: Susanna Price (London, UK) and Alexandre Mebazaa (Paris, FRA)

7:00 PM Adjourn & Dinner

Friday, June 14, 2024

8:00 - 8:30 AM Welcome Coffee

8:30 AM - 8:40 AM

Introduction on behalf of the scientific committee by Alexandre Mebazaa (Paris, FRA)

8:40 AM - 11:00 AM

Session 6: Acute Heart Failure: What trials are still needed?

Moderated by Ileana Piña (Cleveland, USA) and Christopher O’Connor (Falls Church, USA)

Speakers (10 minutes each)

• Primary objectives in implementation RCTs: Harriette Van Spall (Hamilton, CAN)

• STRONG-HF: Gad Cotter (Momentum Research, USA)

• What trials I need for my daily practice? Christopher O’Connor (Falls Church, USA)

• Combining effective oral therapies Alexandre Mebazaa (Paris, FRA)

• How to assess combining GDMT and devices? Biykem Bozkurt (Houston, USA)

• Concepts for ADHF Therapeutic Development Mona Fiuzat (Arlington, USA)

• Role of nurses and APPs in implementing therapies: Carolyn Rosner (Falls Church, USA)

• Worsening Heart Failure: how to improve implementation of heart therapies?: Annette Kent (FIRE1, USA)

Discussants (5 minutes each)

• Industry perspective: Hela Ben Hamouda (Medtronic, FRA), Harjeet Caberwal (Boehringer Ingelheim, USA) & Juuso Blomster (CardioSignal, FIN)

• Start-up perspective: Arnaud Rosier (Implicity, USA)

• Patient's perspective: Rhonda Monroe (Charlotte, USA)

Panel discussion

Moderated by Ileana Piña (Cleveland, USA) and Christopher O’Connor (Falls Church, USA)

Harriette Van Spall (Hamilton, CAN), Gad Cotter (Momentum Research, USA), Christopher O’Connor (Falls Church, USA), Alexandre Mebazaa (Paris, FRA), Biykem Bozkurt (Houston, USA), Mona Fiuzat (Arlington, USA), Carolyn Rosner (Falls Church, USA), Annette Kent (FIRE1, USA), Hela Ben Hamouda (Medtronic, FRA), Harjeet Caberwal (Boehringer Ingelheim, USA), Juuso Blomster (CardioSignal, FIN), Arnaud Rosier (Implicity, USA), Rhonda Monroe (Charlotte, USA), Andrew Farb, (FDA, USA), EMA, NIH/NHLBI

Paper: Mattia Arrigo (Zurich, SUI) & Carine Hamo (Falls Church, USA)

11:00 - 11:30 AM   Coffee Break

11:00 AM - 1:00 PM

Session 7: Management of massive bleeding

Moderated by Sean Collins (Nashville, USA) and Wesley Self (Nashville, USA)

Speakers (10 minutes each)

• Current global recommendations: Natalie Kreitzer (Cincinatti, USA)

• Clinical considerations in hemorrhagic shock in the acute setting: Amelia Maiga (Nashville, USA)

• Investigator’s perspective: Ashkan Shoamanesh (Toronto, CAN)

• How to generate evidence to manage surgical hemorrhagic shock: Jennifer Gurney (Houston, USA)

Discussants (5 minutes each)

• Industry perspective: Anna Sundgren (AstraZeneca, USA), Sergio Molina (Grifols, USA), George Sopko (NHLBI, USA)

Panel discussion

Moderated by Sean Collins (Nashville, USA) and Wesley Self (Nashville, USA)

Natalie Kreitzer (Cincinatti, USA), Amelia Maiga (Nashville, USA), Stuart Connolly (Toronto, CAN), Jennifer Gurney (Houston, USA), Martin Cowie (AstraZeneca, USA), Sergio Molina (Grifols, USA), George Sopko (NHLBI, USA) & OctaPharma), Tek Lamichhane (FDA, USA), George Gibeily (FDA, USA) & EMA

1:00 - 2:00 PM Lunch Break

2:00 - 4:30 PM

Session 8: Improving outcomes in the critically ill patients: AI and physicians working hand-in-hand

Moderated by Michael Harhay (Philadelphia, USA) and Etienne Gayat (Paris, FRA)

Keynote lecture (20 minutes)

• AI-based algorithms used in critical care: Roy Adams (Baltimore, USA)

Speakers (10 minutes each)

• How AI will transfer clinical trials: Bradley Maron (New Haven, USA)

• AI in ICU: run or hug?: Michael Harhay (Philadephia, USA)

• How can AI help research in my company?: Anna Sundgren (AstraZeneca, USA)

• Digital twin in ICU: is the road clear?: Reinhard Laubenbacher (Gainesville, USA)

Discussants (5 minutes each)

• Regulatory Perspectives on Artificial Intelligence & Machine Learning: Stephen Browning (FDA, USA)

• Editor’s perspective: Romain Pirracchio (San Francisco, USA)

• Industry perspective: Mark-Holger Konrad (Philips, USA), & Shan Jegatheeswaran (J&J)

• How AI start-ups are improving critical care outcomes: Christine Gouillard (Us2.ai, USA), Anis Ghorbel (Precisia Care, SUI), Danielle Bergman (JvionAI, USA), David Talby (johnsnowlabs.com), Quentin François (Previa Medical), Inger Persson / David Becedas (AlgoDx) & TBD (Abionic)

Panel discussion

Moderated by Michael Harhay (Philadelphia, USA) and Etienne Gayat (Paris, FRA)

Roy Adams (Baltimore, USA), Bradley Maron (New Haven, USA), Michael Harhay (Philadephia, USA), Anna Sundgren (AstraZeneca, USA), Romain Pirracchio (San Francisco, USA), Mark-Holger Konrad (Philips, USA), Shan Jegatheeswaran (J&J), Christine Gouillard (Us2.ai, USA), Anis Ghorbel (Precisia Care, SUI), Danielle Bergman (JvionAI, USA), David Talby (John Snow Labs, Quentin François (Previa Medical), Inger Persson / David Becedas (AlgoDx), TBD (Abionic), Hetal Odobasic (FDA, USA), EMA, NIH/NHLBI

Paper: Baptiste Vasey (Oxford, GBR)

4:30 - 5:00 PM Coffee Break

4:30 - 7:00 PM

Session 9: ARDS 2024 guidelines shape trial design

Moderated by Emma Grainger (The Lancet, GBR) & Christina Barkauskas (Durham, USA)

Speakers (10 minutes each)

• New global definition of ARDS: Michael Matthay (San Francisco, USA)

• Impact of the global definition on future trial design: Sarina Saheyta (San Francisco, USA)

• What are the priorities for future clinical trialists: Maurizio Cecconi (Milan, ITA)

• Ongoing large trials with ECMO: Alain Combes (Paris, FRA)

• Lung Division’s support of ARDS, Pneumonia & Sepsis research: Guofei Zhou (NIH, USA)

• C5A: a promising target in ARDS: Martin Witzenrath (Berlin, GER)

Discussants (5 minutes each)

• Patient perspective: Eileen Rubin (Chicago, USA)

• Industry perspective: Niels Riedemann (InflaRx, GER), Axel Vater (Aptarion Biotech, GER) & Negin Hajizadeh (Bayer, USA), Martin Staempfli (CSL Behring, GER)

  Panel discussion

  Moderated by Emma Grainger (The Lancet, GBR) & Christina Barkauskas (Durham, USA)

  Michael Matthay (San Francisco, USA), Sarina Saheyta (San Francisco, USA), Maurizio Cecconi (Milan, ITA), Alain Combes (Paris, FRA), Guofei Zhou (NIH, USA), Martin Witzenrath (Berlin, GER), Eileen Rubin (Chicago, USA), Niels Riedemann (InflaRx, GER), Axel Vater (Aptarion Biotech, GER) & Negin Hajizadeh (Bayer, USA), Martin Staempfli (CSL Behring, GER), EMA, NIH/NHLBI

  Paper: Sarina Saheyta (Baltimore, USA)

7:00 PM Adjourn

7:00 PM Cocktail & Dinner in the Embassy of France, Washington D.C.

Saturday, June 15, 2024

8:00 - 8:30 AM Welcome Coffee

8:30 - 8:35 AM Welcome introduction by Alexandre Mebazaa (Paris, FRA)

8:35 AM - 10:40 AM

Session 10: Sepsis I: Endotype-guided therapy

Moderated by Michelle Chew (Malmö, SWE) & Alexandre Mebazaa (Paris, FRA)

Speaker (10 minutes each)

• Is biomarker-guided therapy ready for prime-time?: Bruno François (Limoges, FRA)

• BOOST: Pierre-François Laterre (Brussels, BEL)

• Septic shock i-Micro: Matthieu Legrand (San Francisco, USA)

• Biological markers for Sepsis trials: Benjamin Chousterman (Paris, FRA)

• Digital biomarkers for Sepsis trials: Nathan Shapiro (New Haven, USA)

Discussants (5 minutes each)

• Industry perspective: Blood Purification in Sepsis: John Kellum (Spectral, USA)

• Industry Perspective: Steffan Witte (Adrenomed, GER), Margarita Salcedo (Inotrem, FRA), Jean-François Llitjos (BioMérieux, FRA), Yinong Zhou (Novartis, USA), Bobby Reddy (Prenosis, USA) & Maria Borentain (Bayer, USA), Bastiaan Van Holthe (Roche, CHE)

• Regulator's Perspective: EMA, FDA & PMDA

Panel discussion

Moderated by Michelle Chew (Malmö, SWE) & Alexandre Mebazaa (Paris, FRA)

Bruno François (Limoges, FRA), Pierre-François Laterre (Brussels, BEL), Matthieu Legrand (San Francisco, USA), Benjamin Chousterman (Paris, FRA), Nathan Shapiro (New Haven, USA), Steffan Witte (Adrenomed, GER), Margarita Salcedo (Inotrem, FRA), Jean-François Llitjos (BioMérieux, FRA), Yinong Zhou (Novartis, USA), Bobby Reddy (Prenosis, USA) & Maria Borentain (Bayer, USA), Bastiaan Van Holthe (Roche, CHE), John Kellum & Debra Foster (Spectral, USA), EMA, NIH/NHLBI

Paper: Adrien Picod (Paris, FRA)

10:40 AM - 11:00 AM Coffee Break

11:00 AM - 1:00 PM

Session 11: Sepsis II: Trialists and regulators: can we agree on an endpoint?

Moderated by Nathan Nielsen (Albuquerque, USA) & Diana Stanley (The Lancet, USA)

Speakers (10 minutes each)

• Mortality is dead: Ashish Khanna (Winston-Salem, USA)

• Change in sofa score: Alexandre Mebazaa (Paris, FRA)

• Improvement in organ perfusion: François Dépret (Paris, FRA)

• Organ dysfunction: Jean-Jacques Garaud (Inotrem, FRA)

• Lessons from 2024 European guidelines: Michelle Chew (Malmö, SWE)

Discussants (5 minutes each)

• Patient's Perspective: Eileen Rubin (Chicago, USA)

• Industry Perspective: Maria Borentain (Bayer, USA)

• Regulator's Perspective: EMA, FDA & PMDA

Panel discussion

Moderated by Nathan Nielsen (Albuquerque, USA) & Diana Stanley (The Lancet, USA)

Ashish Khanna (Winston-Salem, USA), TBD, François Dépret (Paris, FRA), Jean-Jacques Garaud (Inotrem, FRA), Michelle Chew (Malmö, SWE), Eileen Rubin (Chicago, USA), Oren Hershkovitz (Enlivex, ISR), Maria Borentain (Bayer, USA), FDA, EMA, PMDA & NIH/NHLBI

1:00 PM Adjourn & Lunch

Please note: the program above is only indicative and is not yet confirmed. Speakers may be changed according to their availability.

For past editions’ scientific programs, click on the links below: